You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,251,587


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,251,587
Title: Method for determining the prognosis of a patient with a neurological disease
Abstract:The present invention provides a method for the determining the prognosis for a patient diagnosed with a neurological disease. The present invention also provides a method for the identification of human subjects for placement in clinical drug trials of drugs being tested for the treatment of neurological disease and for determining a patient\'s future disease risk.
Inventor(s): Sevigny; Pierre (Montreal, CA), Wiebusch; Heiko (Montreal, CA), Schappert; Keith (Montreal, CA)
Assignee: Nova Molecular, Inc. (Montreal, CA)
Application Number:08/991,850
Patent Claims:1. A method of determining the prognosis for a patient already diagnosed with one of the following neurological diseases: Parkinson's disease, multiple sclerosis, or stroke, said method comprising:

a) identifying a patient with said disease;

b) determining the apoE genotype or phenotype of said patient;

c) converting the data obtained in step b) into a prognosis for said patient.

2. The method of claim 1, wherein said prognosis includes a prediction of drug efficacy, patient outcome, or a forecast of patient disease risk.

3. The method of claim 1, wherein the method further comprises determining the BChE genotype or phenotype of said patient.

4. The method of claim 1, wherein said method further comprises obtaining a patient profile.

5. The method of claim 4, wherein said patient profile includes a determination of said patient's sex.

6. The method of claim 4, wherein said patient profile includes the genotype of said patient.

7. The method of claim 4, wherein said patient profile includes the age of said patient.

8. A method for identifying a patient in a clinical trail of a drug for the treatment of one of the following neurological diseases: Parkinson's disease, multiple sclerosis, or stroke, said method comprising:

a) identifying a patient already diagnosed with said disease or as being predisposed to acquire or be at risk for said disease;

b) determining the apoE genotype or phenotype of said patient;

c) converting the data obtained in step b) and determining the prognosis of said patient, said prognosis including a prediction of whether the patient is a candidate for a drug trial for the treatment of said disease.

9. The method of claim 8, wherein said method further comprises determining the BChE genotype or phenotype of said patient.

10. The method of claim 8 wherein said drug is from the group comprising antithrombotics, cholinomimetics, dopaminergics, and interferon .beta.-1B.

11. The method of claim 8 wherein said drug is tacrine.

12. The method of claim 8 wherein said patient is asymptomatic.

13. A method of determining a prognosis of future risk of a neurological disease, selected from the group consisting of Parkinson's disease, multiple sclerosis, and stroke, for a mammal asymptomatic for said disease, said method comprising:

a) determining the apoE genotype or phenotype of said mammal;

b) converting the data obtained in step a) into a prognosis for said mammal, said prognosis including a prediction of said mammal's future disease risk, drug treatment efficacy for said disease, or treatment outcome.

14. The method of claim 13, wherein said mammal is a human.

15. The method of claim 13, wherein the method further comprises determining the BChE genotype or phenotype of said mammal.

16. The method of claim 13, wherein said method further comprises obtaining a patient profile of said mammal.

17. The method of claim 16 wherein said patient profile includes a determination of said mammal's sex.

18. The method of claim 16, wherein said patient profile includes the genotype of said mammal.

19. The method of claim 16, wherein said patient profile includes the age of said mammal.

20. The method of claim 1, wherein the presence of at least one apoE4 allele worsens said prognosis.

21. The method of claim 1, wherein said patient is diagnosed as having stroke or as being predisposed to sustain a stroke.

22. The method of claim 1, wherein said patient is diagnosed as having Parkinson's disease or as being predisposed to acquire Parkinson's disease.

23. The method of claim 1, wherein said patient is diagnosed as having multiple sclerosis or as being predisposed to acquire multiple sclerosis.

24. The method of claim 8, wherein said drug is levodopa-carbidopa.

25. The method of claim 8, wherein said drug is selected from the group consisting of aspirin and ticlopidine.

Details for Patent 6,251,587

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 07/23/1993 ⤷  Try a Trial 2039-03-29
Novartis Pharmaceuticals Corporation EXTAVIA interferon beta-1b For Injection 125290 08/14/2009 ⤷  Try a Trial 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.